The Innovative Medicines Initiative (IMI) is a public private partnership and has therefore a different funding model from other collaborative research consortia in Horizon 2020. Here’s how it works:
- IMI projects are implemented by public-private consortia that consist typically of several companies and several public partners (such as academia, governmental and non governmental organisations, SMEs, etc.).
- Industry does not receive any public funding (EU grants). The cost of resources invested in a project (time of experts, samples, studies, consumables, subcontracted work, cash, etc.) is not claimed back – it is EFPIA’s in-kind contribution to IMI projects. You can follow the complete funding flow as explained in our infographic.